雷帕鸣(西罗莫司片)怎么购买？

It is a macrolide antibiotic immunosuppressant. It is mainly used clinically to treat kidney transplant patients to avoid rejection due to organ transplantation. How to buy Rapamin (sirolimus tablets)?

Purchasing channels for Rapamin: Rapamin is already on the market in China. Patients can purchase it at major hospitals or pharmacies in China with a prescription issued by a doctor!

When it comes to buying medicines, the first thing that comes to mind is the price. Compared with foreign countries, the domestic prices are not very affordable. It is understood that the relatively low price currently on the market is rapamin (sirolimus tablets) produced by the Indian Biocon Pharmaceutical Factory. The specification is 1mg*10 tablets and the price is around 200$. Due to the floating exchange rate, the price is different. Please consult the medical companion for the specific price!

If you want to buy Rapazone that is marketed abroad, but it is inconvenient to go abroad, the most reliable way is to buy it through a formal overseas medical service institution in China, which will sign a guarantee contract for you. The medicine and money will not be handled by it, and will be mailed to the patient by direct mail, guaranteeing 100% authenticity!

How to take Rapamin: Orally, once a day.

Concomitant use with cyclosporine and corticosteroids is recommended.

It should be started as soon as possible after transplantation. For new transplant recipients, the loading dose that should be taken for the first time is three times the maintenance dose. The recommended loading dose for kidney transplant patients is 6 mg and the maintenance dose is 2 mg/day.

It has serious side effects. It can cause high blood pressure and tachycardia, and can also cause thrombocytopenia, hypotension, hyperlipidemia and lymphocele. When taking it, you must take it under the guidance of a doctor, and you must not use it indiscriminately. The dose should be reduced in patients with liver dysfunction.

Recommended related hot articles: /newsDetail/85019.html